Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.

Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB.

J Manag Care Spec Pharm. 2016 Sep;22(9):1072-84. doi: 10.18553/jmcp.2016.22.9.1072.

2.

Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.

Wielage RC, Perk S, Campbell NL, Klein TM, Posta LM, Yuran T, Klein RW, Ng DB.

J Med Econ. 2016 Dec;19(12):1135-1143. Epub 2016 Jul 4.

PMID:
27326725
3.

Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder.

Suehs BT, Davis C, Franks B, Yuran TE, Ng D, Bradt J, Knispel J, Vassilakis M, Berner T.

J Am Geriatr Soc. 2016 Apr;64(4):779-87. doi: 10.1111/jgs.14030. Epub 2016 Apr 5.

PMID:
27059714
4.

Detection of measles virus RNA in urine specimens from vaccine recipients.

Rota PA, Khan AS, Durigon E, Yuran T, Villamarzo YS, Bellini WJ.

J Clin Microbiol. 1995 Sep;33(9):2485-8.

5.

Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975.

Massung RF, Liu LI, Qi J, Knight JC, Yuran TE, Kerlavage AR, Parsons JM, Venter JC, Esposito JJ.

Virology. 1994 Jun;201(2):215-40.

PMID:
8184534
6.

Potential virulence determinants in terminal regions of variola smallpox virus genome.

Massung RF, Esposito JJ, Liu LI, Qi J, Utterback TR, Knight JC, Aubin L, Yuran TE, Parsons JM, Loparev VN, et al.

Nature. 1993 Dec 23-30;366(6457):748-51.

PMID:
8264798

Supplemental Content

Support Center